

Literatur

1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med*. 2015;373:23-34. doi:10.1056/NEJMoa1504030.
2. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. *J Clin Oncol*. 2022;40:127-137. doi:10.1200/JCO.21.02229.
3. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med*. 2017;377:1824-1835. doi:10.1056/NEJMoa1709030.
4. Patel SP, Othus M, Chen Y, et al. Neoadjuvant-Adjuvant Pembrolizumab versus Adjuvant Pembrolizumab in Resectable Stage III-IV Melanoma. *N Engl J Med*. 2023;388:813-823. doi:10.1056/NEJMoa2211437.
5. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2022;33:1217-1238. doi:10.1016/j.annonc.2022.10.001.
6. Cortes J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. *N Engl J Med*. 2022;386:1143-1154. doi:10.1056/NEJMoa2115022.
7. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. *N Engl J Med*. 2022;387:9-20. doi:10.1056/NEJMoa2203690.
8. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: DESTINY-PanTumor02. *J Clin Oncol*. 2024;42:47-58. doi:10.1200/JCO.23.02005.
9. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. *N Engl J Med*. 2021;384:1125-1135. doi:10.1056/NEJMoa2035807.
10. Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. *N Engl J Med*. 2024;390:875-888. doi:10.1056/NEJMoa2312117.
11. Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab Soravtansine in FRalpha-Positive, Platinum-Resistant Ovarian Cancer. *N Engl J Med*. 2023;389:2162-2174. doi:10.1056/NEJMoa2309169.
12. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2022;386:351-363. doi:10.1056/NEJMoa2115304.
13. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. *N Engl J Med*. 2022;387:495-505. doi:10.1056/NEJMoa2203478.

14. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. *N Engl J Med*. 2022;387:2232-2244. doi:10.1056/NEJMoa2204591.
15. Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. *N Engl J Med*. 2023;389:2063-2075. doi:10.1056/NEJMoa2307980.
16. Robert C, Long Georgina V., Brady B., et al.: Nivolumab in Previously Untreated Melanoma without BRAF Mutation. *N. Engl. J. Med*. 2015;372:320-330. doi: 10.1056/NEJMoa1412082
17. Vega G, Morillo D, Riedhammer C., et al.: Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myelom. *Blood* (2025) 146 (Supplement1): 5757. doi.org/10.1182/blood-2025-5757